These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 17109596)
1. A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus. McCall AL; Cox DJ; Crean J; Gloster M; Kovatchev BP Diabetes Technol Ther; 2006 Dec; 8(6):644-53. PubMed ID: 17109596 [TBL] [Abstract][Full Text] [Related]
2. Pramlintide reduces the risks associated with glucose variability in type 1 diabetes. Kovatchev BP; Crean J; McCall A Diabetes Technol Ther; 2008 Oct; 10(5):391-6. PubMed ID: 18715216 [TBL] [Abstract][Full Text] [Related]
3. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Kovatchev BP; Clarke WL; Breton M; Brayman K; McCall A Diabetes Technol Ther; 2005 Dec; 7(6):849-62. PubMed ID: 16386091 [TBL] [Abstract][Full Text] [Related]
4. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651 [TBL] [Abstract][Full Text] [Related]
5. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study. Riddle MC; Nahra R; Han J; Castle J; Hanavan K; Hompesch M; Huffman D; Strange P; Öhman P Diabetes Care; 2018 Nov; 41(11):2346-2352. PubMed ID: 30213882 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of continuous glucose monitoring system (CGMS) to detect postprandial hyperglycemia and unrecognized hypoglycemia in type 1 diabetic patients. Maia FF; Araújo LR Diabetes Res Clin Pract; 2007 Jan; 75(1):30-4. PubMed ID: 16806560 [TBL] [Abstract][Full Text] [Related]
7. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Ryan GJ; Jobe LJ; Martin R Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288 [TBL] [Abstract][Full Text] [Related]
8. Glucose sensor evaluation of glycemic instability in pediatric type 1 diabetes mellitus. Alemzadeh R; Loppnow C; Parton E; Kirby M Diabetes Technol Ther; 2003; 5(2):167-73. PubMed ID: 12871606 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of continuous glucose monitoring system to detect unrecognized hypoglycemia in children and adolescents with type 1 diabetes. Maia FF; Araújo LR Arq Bras Endocrinol Metabol; 2005 Aug; 49(4):569-74. PubMed ID: 16358087 [TBL] [Abstract][Full Text] [Related]
10. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Tanenberg R; Bode B; Lane W; Levetan C; Mestman J; Harmel AP; Tobian J; Gross T; Mastrototaro J Mayo Clin Proc; 2004 Dec; 79(12):1521-6. PubMed ID: 15595336 [TBL] [Abstract][Full Text] [Related]
11. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746 [TBL] [Abstract][Full Text] [Related]
12. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Hay LC; Wilmshurst EG; Fulcher G Diabetes Technol Ther; 2003; 5(1):19-26. PubMed ID: 12725703 [TBL] [Abstract][Full Text] [Related]
13. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes. Amiel SA; Heller SR; Macdonald IA; Schwartz SL; Klaff LJ; Ruggles JA; Weyer C; Kolterman OG; Maggs DG Diabetes Obes Metab; 2005 Sep; 7(5):504-16. PubMed ID: 16050943 [TBL] [Abstract][Full Text] [Related]
14. Impact of Use Frequency of a Mobile Diabetes Management App on Blood Glucose Control: Evaluation Study. Vehi J; Regincós Isern J; Parcerisas A; Calm R; Contreras I JMIR Mhealth Uhealth; 2019 Mar; 7(3):e11933. PubMed ID: 30843865 [TBL] [Abstract][Full Text] [Related]
15. Assessment of glycemic control after islet transplantation using the continuous glucose monitor in insulin-independent versus insulin-requiring type 1 diabetes subjects. Paty BW; Senior PA; Lakey JR; Shapiro AM; Ryan EA Diabetes Technol Ther; 2006 Apr; 8(2):165-73. PubMed ID: 16734547 [TBL] [Abstract][Full Text] [Related]
16. The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Heptulla RA; Rodriguez LM; Bomgaars L; Haymond MW Diabetes; 2005 Apr; 54(4):1100-7. PubMed ID: 15793249 [TBL] [Abstract][Full Text] [Related]
17. Restoring euglycemia in the basal state using continuous glucose monitoring in subjects with type 1 diabetes mellitus. Zisser HC; Bevier WC; Jovanovic L Diabetes Technol Ther; 2007 Dec; 9(6):509-15. PubMed ID: 18034605 [TBL] [Abstract][Full Text] [Related]
18. [Metabolic/glycemic control accuracy, effect and complications of the continuous glucose monitoring system in diabetic patients]. Maia FF; Araújo LR Rev Assoc Med Bras (1992); 2006; 52(6):395-400. PubMed ID: 17242774 [TBL] [Abstract][Full Text] [Related]
19. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. Singh-Franco D; Robles G; Gazze D Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279 [TBL] [Abstract][Full Text] [Related]
20. [Usefulness of continuous glucose monitoring system (CGMS) in monitoring glycaemic profile in small children with diabetes type 1]. Głowińska-Olszewska B; Urban M; Peczyńska J; Florys B; Kowalewski M Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(4):237-43. PubMed ID: 16232362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]